PR Newswire

October 21, 2025

Crystalys Therapeutics Advances Phase 3 Trials of Dotinurad for the Treatment of Gout with Dosing of First Patients

read more →

September 30, 2025

Crystalys Therapeutics Launches with $205M Series A Financing to Transform the Treatment of Gout

read more →